HomeMOLN • NASDAQ
Molecular Partners AG
add
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (CHF) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 0.00 | -100.00% |
Operating expense | 5.35M | -7.37% |
Net income | -11.23M | 43.22% |
Net profit margin | — | — |
Earnings per share | -0.30 | — |
EBITDA | -14.55M | 11.39% |
Effective tax rate | -0.02% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (CHF) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 149.44M | -20.04% |
Total assets | 158.53M | -20.08% |
Total liabilities | 16.89M | -22.95% |
Total equity | 141.64M | — |
Shares outstanding | 36.86M | — |
Price to book | 1.12 | — |
Return on assets | -23.65% | — |
Return on capital | -25.90% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (CHF) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -11.23M | 43.22% |
Cash from operations | -13.20M | 17.47% |
Cash from investing | -4.49M | -123.10% |
Cash from financing | 15.30M | 5,234.56% |
Net change in cash | -1.88M | -72.29% |
Free cash flow | -6.34M | 32.28% |
Previous close
$4.31
Day range
$4.33 - $4.35
Year range
$3.32 - $12.70
Market cap
171.62M USD
Avg Volume
2.62K
About
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Founded
2004
Website
Employees
159
